The evidence base around oral nicotine pouches is developing rapidly. A major updated scoping review published in Nicotine & Tobacco Research in September 2026 provides one of the broadest assessments so far, examining research on product characteristics, patterns of use, nicotine delivery, toxicity, marketing and potential public-health effects.
The review identified 73 new studies, bringing the combined evidence base with an earlier review to 135 studies. Its central toxicological finding is significant: oral nicotine pouches appear to be considerably less toxic than combustible cigarettes. At the same time, the researchers stress that their long-term health effects remain insufficiently studied.
A Clear Difference in Toxicant Exposure
The distinction between nicotine pouches and cigarettes begins with how the products work. Cigarettes burn tobacco, generating smoke containing numerous toxic and carcinogenic substances. Nicotine pouches contain no tobacco leaf and require no combustion or inhalation.
Studies reviewed by the researchers generally found substantially lower exposure to harmful substances among people using nicotine pouches compared with cigarette smokers. Biomarker research, for example, has reported lower levels of several toxicants among exclusive pouch users, although some of these studies involved relatively small samples and should therefore be interpreted cautiously.
These findings strengthen the case for recognising differences between nicotine products according to their toxicological profiles. Lower exposure, however, should not be interpreted as an absence of risk. Nicotine is addictive, individual pouch formulations differ, and research has identified potential concerns associated with some ingredients and contaminants. Recent research on nicotine products has also highlighted the importance of monitoring substances such as heavy metals.
Nicotine Strength Matters
The review also shows why nicotine pouches should not be treated as a single, uniform product category. Nicotine delivery varies considerably according to product strength, formulation and release characteristics.
Some higher-strength pouches can produce nicotine exposure exceeding that of cigarettes in adult smokers. Research reviewed by the authors also found acute increases in heart rate, blood pressure and arterial stiffness with high-strength products. These short-term physiological effects do not demonstrate equivalent long-term disease risk to smoking, but they do reinforce the importance of appropriate product standards and strength considerations.
A proportionate regulatory framework therefore needs to account for differences both between product categories and within them. Product standards covering nicotine content, ingredients, manufacturing quality and appropriate consumer information can help address avoidable risks without assuming that every nicotine product presents the same risk profile.
What Do We Know About Smoking Reduction?
Evidence on whether nicotine pouches can help smokers move away from cigarettes remains much less developed.
The review identified small, short-term studies in which smokers using nicotine pouches reduced their cigarette consumption. Complete switching was uncommon, however, and dual use remained frequent. The researchers therefore concluded that there is currently insufficient evidence to establish oral nicotine pouches as a smoking-cessation aid.
This distinction matters. Evidence that a product exposes users to fewer toxicants than cigarettes does not automatically demonstrate that it will produce successful long-term smoking cessation at population level. Those are separate research questions requiring longer-term behavioural and epidemiological evidence.
Youth Uptake Requires Continued Attention
The potential harm-reduction value of nicotine pouches for adults who smoke also needs to be considered alongside uptake among people who do not currently use nicotine.
In the United States, the National Youth Tobacco Survey recorded current nicotine pouch use among 1.8% of middle and high school students in 2024, compared with 0.8% in 2021. The updated review also identified increasing sales and growing use of online and social-media marketing.
These trends support continued surveillance and credible youth-protection measures. Age restrictions, responsible marketing rules, product standards and enforcement against non-compliant products can form part of a regulatory framework designed to limit youth access while recognising differences in risk between combustible and non-combustible products.
Regulation Should Follow the Evidence
The updated evidence provides further support for a basic principle of risk-proportionate nicotine regulation: different products should be assessed according to their characteristics and evidence base rather than assumed to carry equivalent risks.
For nicotine pouches, current research points towards substantially lower toxicant exposure than cigarette smoking, while important uncertainties remain around long-term health outcomes, patterns of dual use, cessation effectiveness and the effects of different formulations and nicotine strengths. The review itself also has limitations. The authors did not formally assess risk of bias for each included study, and 12 of the 73 newly identified studies received industry funding.
These uncertainties are a reason for stronger independent research and surveillance. They are not a reason to disregard the toxicological differences already identified.
For regulators, the challenge is to develop safeguards that address genuine risks while maintaining meaningful distinctions between products. A framework built around evidence, product standards, youth protection and proportionality offers a more credible basis for nicotine policy than treating all forms of nicotine use as equivalent.
